9342-8530 Quebec Inc DGCRF

RE: New US patent for PCA3

[ready2go1]

Great to see some news. I have had a couple calls about what I meant in terms of what the Urologist has said in the past. What I have found most interesting is the time that it takes a hospital to have its own internal board approve an ASR test. During this time, GPRO does not promote or market, it must come from within the hospital itself. In the case of my hospital, it took two years(with me pushing everyday). They missed a board meeting by 4 months and had to submit for the following year and even after it was given the OK, the lab had to get set up (lazy). Point being is that sales could be at least 5-6 times what we are currently seeing. The urologist has said that he uses the current tools he has to help patients and himself determine what route to take. When they ask about pca3, he remarks that it is not FDA approved but they will have it available once it is. (hospital lab is not running the test yet)
     He laughs, when we talk about how much it is discussed at meetings and classes he attends but Gen-Probe and Diagnocure's name are never brought up. They are not investors but urologist's that are awaiting approval of the test. Thats why he continues to tell me, just to sit back and wait, and not to force the issue. PCA3 will be adopted quickly and will be used to help and identify many that are at risk for prostate cancer. Point to all of this is that after 10 yrs this is still a well kept secret  that the U.S. investor is not aware of.
     I look for us to get approved ($4.00), gain some footing, raise some cash (down the road) and list in the U.S (>$5.00).
This is a $10.00 stock if we can stay out of the hands of Gen-Probe and anyone who acquires them.